Clinical trials: Amyloid Beta-protein
Geographic Atrophy of the Macula
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina.
- Trial name
- eDREAM (NCT06659549)
- Testing
- GAL-101
- Where
- 24 sites in United States, Armenia and 6 more
- Volunteers
- 110 people
- Sponsor
- Galimedix Therapeutics Inc
Alzheimer's Disease
Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
The underlying goal of this study is to assess 123-I MNI-168 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of Alzheimer's Disease (AD) research participants and similarly aged and gender matched healthy…
- Trial name
- NCT00870519
- Testing
- I-123-MNI-168, 123-I MNI-168
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease
Evaluation of [123I] MNI-308 and SPECT as a Marker of Beta-amyloid Protein Deposition in AD Subjects Compared to HC
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-308, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT)…
- Trial name
- NCT00544453
- Testing
- [123I] MNI-308
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer Disease
Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
This study will look at the effects of lemborexant on Alzheimer's disease biomarkers found in the cerebrospinal fluid (CSF) and blood in individuals who are poor sleepers
- Trial name
- NCT05728736
- Testing
- Lemborexant 25 mg
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Brendan Lucey
Alzheimer's Disease
Modeling the Relationships Between Functional Connectivity and Amyloid Deposition in Alzheimer's Disease
Glucose is the main energy source of brain. Different neural degenerative diseases such as Parkinson's disease or Alzheimer's disease have shown distinct brain glucose metabolic patterns.
- Trial name
- NCT04174287
- Testing
- F-18-AV45
- Where
- Taiwan
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Alzheimer's Disease
Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT)…
- Trial name
- NCT00968097
- Testing
- 123-I MNI-340
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Preclinical Alzheimer's Disease, Alzheimer's Disease (AD)
Alzheimer's Plasma Extension
The goal of this observational study is to learn how Alzheimer's disease-related blood biomarkers, brain amyloid, and memory and thinking abilities change over time.
- Trial name
- APEX (NCT06416072)
- Testing
- NAV4694
- Where
- 56 sites in United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Down Syndrome (DS), Down Syndrome (Trisomy 21)
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
The goal of this clinical trial is to learn if donanemab can reduce levels of amyloid in the brain, and if donanemab is safe and well-tolerated in participants with Down syndrome.
- Conditions
- Down Syndrome (DS), Down Syndrome (Trisomy 21), Alzheimer Disease, Amyloid Beta Protein
- Trial name
- ALADDIN (NCT06911944)
- Testing
- Donanemab
- Volunteers
- 60 people
- Sponsor
- Michael Rafii, MD, PhD
Normal Physiology
Brain Amyloid- Retention During Wakefulness and Following Emergence From Sleep in Healthy People
Background: Brain activity creates waste products. The body s glymphatic system removes this waste, especially during sleep. One brain waste product is amyloid-beta (Ab). It plays a role in Alzheimer s disease.
- Trial name
- NCT02669225
- Testing
- [18F]florbetaben
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Alzheimers Disease
Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls
The underlying goal of this study is to assess 123-I AV83 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
- Trial name
- NCT00448799
- Testing
- [123-I] AV-83 Injection and Imaging Procedures
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer Disease, Amyloid Beta-Protein
Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers
The aim of this study is to evaluate the efficacy, safety of a single dose of BAY 94-9172 (ZK 6013443) as an investigational medicinal product (IMP) in detecting cerebral protein-plaque (amyloid beta) with positron emission…
- Trial name
- NCT00750282
- Testing
- Florbetaben (BAY94-9172)
- Where
- 23 sites in United States, Australia and 3 more
- Volunteers
- 422 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer Disease, Amyloid Beta-Peptides
Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)
This study is intended to examine the impact of learning amyloid brain imaging results among asymptomatic older adults, and how to safely communicate these results and educate on the risk of developing Alzheimer's disease.
- Conditions
- Alzheimer Disease, Amyloid Beta-Peptides, Risk Assessment, Education
- Trial name
- REVEAL-SCAN (NCT02959489)
- Testing
- Alzheimer's Disease Risk Disclosure, Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure
- Where
- 4 sites in United States
- Volunteers
- 315 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Alzheimer's Disease
CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease
Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests.
- Trial name
- NCT02021682
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Healthy Aging, Brain Health
Assessing the Influence of Habitual Beef Intake on Key Molecular Markers of Brain Health
his study investigates whether eating lean beef every day can help support brain health and healthy aging in older adults. As people age, protecting memory and cognitive function becomes increasingly important.
- Conditions
- Healthy Aging, Brain Health, Cardiometabolic Health, Normal Aging
- Trial name
- NCT07623785
- Testing
- Lean Beef, Non-Beef Control
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- South Dakota State University
Alzheimer Disease, Alzheimer Dementia
Study to Evaluate Amyloid in Blood and Imaging Related to Dementia
The purpose of this study is to determine how well a blood test can detect amyloid beta, a protein involved in Alzheimer's disease.
- Trial name
- SEABIRD (NCT03899844)
- Testing
- Blood collection, PiB PET/MRI, and cognitive testing
- Where
- United States
- Volunteers
- 1,122 people
- Sponsor
- Washington University School of Medicine
Alzheimer Disease
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
The main objectives of this proposal are as follows: To assess the dynamic uptake and washout of 123-I AV51, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in…
- Trial name
- NCT00556660
- Testing
- [123I] AV-151
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Atrophy, Geographic
Pharmacokinetic (PK) Study of GSK933776 in Healthy Volunteers
This study is intended to enable a possible transition to intramuscular (IM) or subcutaneous (SQ) administration for subsequent studies with GSK933776 by characterizing the safety, tolerability, PK and pharmacodynamic profiles…
- Trial name
- NCT02033668
- Testing
- GSK933776 for SQ administration, GSK933776 for IM administration, GSK933776 for IV administration
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Stress Reaction, Stress Physiology
Acute Plasma Abeta Responses to Stress
Research has shown that activation of the sympathetic nervous system for extended periods or during certain times in life can increase the risk for Alzheimer's disease.
- Trial name
- NCT05521919
- Testing
- Sympathetic Nervous System Activation, No-stress
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Mild to Moderate Alzheimer's Disease
A 28-Day Study of GAL-101 in Participants With Mild to Moderate Alzheimer's Disease
This Phase 2a study will evaluate the safety and tolerability of GAL-101 in approximately 100 participants with mild to moderate Alzheimer's disease associated with amyloid-beta pathology.
- Trial name
- SAPHARY (NCT07789873)
- Testing
- GAL-101 Salt
- Volunteers
- 100 people
- Sponsor
- Galimedix Therapeutics Inc
Alzheimer's Disease
Amyloid-beta PET Imaging With 18F-92 in Alzheimer's Disease
Alzheimer's disease is a neurodegenerative disease. Numerous studies have reported that β-amyloid (Aβ) is an important marker for the diagnosis of AD.
- Trial name
- NCT04926272
- Testing
- 18F-92
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Fujian Medical University